Genotoxicity and mutagenicity in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgico === Chronic myelogenous leukemia (CML) is a myeloproliferative disease of hematopoietic stem cells, characterized by the presence of the Philadelphia (Ph) chromosome, originating from a reciprocal translocation between the long arms of ch...
Main Author: | Pedro Aurio Maia Filho |
---|---|
Other Authors: | RomÃlia Pinheiro GonÃalves Lemes |
Format: | Others |
Language: | Portuguese |
Published: |
Universidade Federal do CearÃ
2017
|
Subjects: | |
Online Access: | http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=19044 |
Similar Items
-
Expression and mutational profile of BCR-ABL gene in patients with chronic mieloid leukemia treated with tyrosine kinase inhibitors
by: TarcÃsio Paulo de Almeida Filho
Published: (2017) -
Cardiovascular risk reduction in chronic myeloid leukemia patients treated with the tyrosine kinase inhibitors
by: N. Lopina, et al.
Published: (2020-10-01) -
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
by: Mario Tiribelli, et al.
Published: (2019-08-01) -
Hodgkin Lymphoma in a Case of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors
by: Smeeta GAJENDRA, et al.
Published: (2019-01-01) -
Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia
by: Stephen E. Langabeer, et al.
Published: (2020-01-01)